| Document |
Document Title |
|
WO/2021/069571A1 |
The present invention relates to a polymorph of lorlatinib and to a process for its preparation. The present invention also relates to solvates of lorlatinib, which can be used as intermediates for the preparation of the polymorph of the...
|
|
WO/2021/063276A1 |
The present invention relates to a macrocyclic derivative, a preparation method therefor and use thereof in medicine. In particular, the present invention relates to a macrocyclic derivative as represented by general formula (I), a prepa...
|
|
WO/2021/067805A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/066873A1 |
The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a ...
|
|
WO/2021/067405A1 |
The present disclosure provides neuroprotective compounds along with their use in treating disease such as Parkinson's disease (PD). The compounds can be used as inhibitors for Parthanatos Associated AIF (apoptosis-inducing factor) Nucle...
|
|
WO/2021/067521A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
|
WO/2021/063346A1 |
A novel KRAS G12C inhibitor. A compound represented by formula (I) and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compound represented by formula (I) and a composition thereof may effectively ...
|
|
WO/2021/067606A1 |
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...
|
|
WO/2021/067335A1 |
The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according t...
|
|
WO/2021/058443A1 |
The invention provides fluorescent probes having the general formula (I) wherein X, Y, L and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2021/058444A1 |
The invention provides new heterocyclic compounds having the general formulae (Ia) and (Ib) (Formula Ia, Ib) wherein A, B, and L are as described herein, compositions including the compounds, processes of manufacturing the compounds and ...
|
|
WO/2021/058416A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, Q, U, V, W, X, Z, m, n, and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds a...
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/057834A1 |
A crystal form of ester compound and a preparation method therefor. The present invention relates to the technical field of pharmaceutical and chemical engineering. The crystal form has good stability, solubility, and powder flowability ...
|
|
WO/2021/055591A1 |
The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, l...
|
|
WO/2021/052447A1 |
A crystal form of a hepatitis B surface antigen inhibitor and a preparation method, and an application of the crystal form in the preparation of the hepatitis B surface antigen inhibitor.
|
|
WO/2021/052499A1 |
Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceuti...
|
|
WO/2021/048241A1 |
The invention provides new radiolabeled monoacylglycerol lipase (MAGL) inhibitors that are useful for medical imaging, such as positron-emission tomography (PET), single-photon emission computed tomography (SPECT) and/or autoradiography.
|
|
WO/2021/048242A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods ...
|
|
WO/2021/047674A1 |
A compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and disclosed is an application thereof in the preparation of a medication for treating diseases related to a CRBN receptor.
|
|
WO/2021/050915A1 |
The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods ...
|
|
WO/2021/048342A1 |
The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2021/047616A1 |
Provided are an oxynitride heterocyclic heptane-based spiro compound, an intermediate and a preparation method therefor. The present invention relates to a preparation method for the compound as shown in formula 7a or formula 8a. The pre...
|
|
WO/2021/047556A1 |
Provided are a nitrogen-containing heterocyclic compound, and a preparation method therefor, a pharmaceutical composition comprising same and the use thereof. Specifically, provided in the present invention is a compound as shown in form...
|
|
WO/2021/048036A1 |
The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R|, R 2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods o...
|
|
WO/2021/047524A1 |
The present invention belongs to the field of medical technology and relates to a class of functional small molecules targeting proteolysis pathways, a preparation and an application thereof. Specifically, the present invention relates t...
|
|
WO/2021/047555A1 |
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...
|
|
WO/2021/043190A1 |
Isoxazolo[5,4-H]quinazoline compounds represented by general formula (I), which can be used to treat cell proliferation disorders, and are effective cyclin-dependent kinase (CDK) inhibitors.
|
|
WO/2021/042178A1 |
This invention relates to methods of treating, preventing, managing and/or controlling opioid withdrawal and/or a symptom associated with the opioid withdrawal. Compounds, compositions, medicaments and kits are provided that may be used ...
|
|
WO/2021/045890A1 |
Selective ratiometric sensors detect biologically-relevant concentrations of potassium ions in aqueous solution at physiological pH as well as in intact, living biological specimens.
|
|
WO/2021/043703A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/042890A1 |
A heterocyclic compound shown in formula I and application thereof as a Trk kinase inhibitor.
|
|
WO/2021/045469A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/043217A1 |
A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof. Specifically, a compound having the structure represented by formula (I), a preparation method therefor and an applicat...
|
|
WO/2021/040310A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element using same.
|
|
WO/2021/039824A1 |
An RNA methyltransferase inhibitor containing at least one type of compound selected from the group consisting of sulfonamide-based compounds represented by general formula (1) and pyrazoline-based compounds represented by general formul...
|
|
WO/2021/031599A1 |
The present invention provides a method for preparing a drug toxin PNU-159682 (morpholinyl anthracycline derivative) of an antibody-conjugated drug, and an intermediate involved in the preparation method. According to the preparation met...
|
|
WO/2021/027566A1 |
Provided is a preparation method for an oxazepine compound, and specifically disclosed are a preparation method for a compound of formula (I) and an intermediate of same.
|
|
WO/2021/029308A1 |
The present invention addresses the problem of providing a novel insecticide for agricultural and horticultural use, the insecticide having a further reduced degree of noxiousness to humans and animals, in agricultural and horticultural ...
|
|
WO/2021/029632A1 |
The invention provides novel substituted heterocyclic compounds represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The co...
|
|
WO/2021/028643A1 |
The application relates to heterocyclic amide derivatives and their use in the treatment and prophylaxis of cancer, and to compositions containing said derivatives and processes for their preparation. (Formula (I))
|
|
WO/2021/030711A1 |
The present disclosure relates to compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these co...
|
|
WO/2021/026100A1 |
Amide compounds of formula (I): as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-relate...
|
|
WO/2021/024202A1 |
The present invention relates to a process for the preparation of an amorphous form of midostaurin with a low content of residual organic solvent.
|
|
WO/2021/023994A1 |
The present invention relates to a crystalline molecular complex comprising pinoxaden and a carboxylic acid. The invention also relates to a process for the preparation of the crystalline molecular complex, a herbicidal composition compr...
|
|
WO/2021/023154A1 |
Disclosed are a compound as shown in formula (I), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.
|
|
WO/2021/020363A1 |
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...
|
|
WO/2021/018194A1 |
Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Fo...
|
|
WO/2020/150473A3 |
The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using t...
|
|
WO/2021/013910A1 |
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly in plants.
|
